25 XP   0   0   10

Ultimovacs ASA
Buy, Hold or Sell?

Let's analyse Ultimovacs together

PenkeI guess you are interested in Ultimovacs ASA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Ultimovacs ASA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Ultimovacs ASA

I send you an email if I find something interesting about Ultimovacs ASA.

Quick analysis of Ultimovacs (30 sec.)










What can you expect buying and holding a share of Ultimovacs? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr8.12
Expected worth in 1 year
kr3.18
How sure are you?
20.8%

+ What do you gain per year?

Total Gains per Share
kr-4.94
Return On Investment
-59.4%

For what price can you sell your share?

Current Price per Share
kr8.31
Expected price per share
kr6.07 - kr59.50
How sure are you?
50%

1. Valuation of Ultimovacs (5 min.)




Live pricePrice per Share (EOD)

kr8.31

Intrinsic Value Per Share

kr-74.39 - kr-87.60

Total Value Per Share

kr-66.27 - kr-79.48

2. Growth of Ultimovacs (5 min.)




Is Ultimovacs growing?

Current yearPrevious yearGrowGrow %
How rich?$25.3m$46.7m-$14.7m-46.0%

How much money is Ultimovacs making?

Current yearPrevious yearGrowGrow %
Making money-$4.2m-$3.8m-$485.7k-11.3%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Ultimovacs (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#555 / 1016

Most Revenue
#799 / 1016

Most Profit
#401 / 1016

Most Efficient
#244 / 1016

What can you expect buying and holding a share of Ultimovacs? (5 min.)

Welcome investor! Ultimovacs's management wants to use your money to grow the business. In return you get a share of Ultimovacs.

What can you expect buying and holding a share of Ultimovacs?

First you should know what it really means to hold a share of Ultimovacs. And how you can make/lose money.

Speculation

The Price per Share of Ultimovacs is kr8.31. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ultimovacs.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ultimovacs, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr8.12. Based on the TTM, the Book Value Change Per Share is kr-1.23 per quarter. Based on the YOY, the Book Value Change Per Share is kr-1.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ultimovacs.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.15-1.8%-0.13-1.6%-0.11-1.3%-0.09-1.1%-0.09-1.0%
Usd Book Value Change Per Share-0.13-1.6%-0.11-1.3%-0.09-1.1%0.020.2%0.030.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.13-1.6%-0.11-1.3%-0.09-1.1%0.020.2%0.030.4%
Usd Price Per Share11.13-9.41-7.28-6.08-5.07-
Price to Earnings Ratio-18.89--18.12--18.23--14.49--12.08-
Price-to-Total Gains Ratio-86.28--91.62--105.51--78.74--78.74-
Price to Book Ratio15.12-10.49-5.47-5.45-4.54-
Price-to-Total Gains Ratio-86.28--91.62--105.51--78.74--78.74-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.752886
Number of shares1328
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.110.02
Usd Total Gains Per Share-0.110.02
Gains per Quarter (1328 shares)-148.5820.89
Gains per Year (1328 shares)-594.3483.57
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-594-60408474
20-1189-11980167158
30-1783-17920251242
40-2377-23860334326
50-2972-29800418410
60-3566-35740501494
70-4160-41680585578
80-4755-47620669662
90-5349-53560752746
100-5943-59500836830

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.024.00.00.0%0.024.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.016.01.015.0%5.018.01.020.8%5.018.01.020.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.024.00.0%0.00.024.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.016.01.015.0%5.018.01.020.8%5.018.01.020.8%

Fundamentals of Ultimovacs

About Ultimovacs ASA

Ultimovacs ASA, a biotech company, develops immunotherapies against cancers. Its lead product candidate is UV1, a peptide-based cancer vaccine that induces a specific T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Fundamental data was last updated by Penke on 2024-04-04 05:32:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Ultimovacs ASA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Ultimovacs earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Ultimovacs to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ultimovacs ASA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--199.6%+199.6%
TTM--213.0%+213.0%
YOY--279.3%+279.3%
5Y--438.4%+438.4%
10Y--605.5%+605.5%
1.1.2. Return on Assets

Shows how efficient Ultimovacs is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Ultimovacs to the Biotechnology industry mean.
  • -16.0% Return on Assets means that Ultimovacs generated kr-0.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ultimovacs ASA:

  • The MRQ is -16.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.0%TTM-11.8%-4.2%
TTM-11.8%YOY-7.7%-4.1%
TTM-11.8%5Y-7.3%-4.6%
5Y-7.3%10Y-7.4%+0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.0%-13.5%-2.5%
TTM-11.8%-12.9%+1.1%
YOY-7.7%-11.8%+4.1%
5Y-7.3%-14.1%+6.8%
10Y-7.4%-16.0%+8.6%
1.1.3. Return on Equity

Shows how efficient Ultimovacs is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Ultimovacs to the Biotechnology industry mean.
  • -20.0% Return on Equity means Ultimovacs generated kr-0.20 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ultimovacs ASA:

  • The MRQ is -20.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.0%TTM-14.1%-5.9%
TTM-14.1%YOY-8.5%-5.6%
TTM-14.1%5Y-8.2%-5.9%
5Y-8.2%10Y-8.3%+0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.0%-16.9%-3.1%
TTM-14.1%-16.1%+2.0%
YOY-8.5%-15.1%+6.6%
5Y-8.2%-19.9%+11.7%
10Y-8.3%-20.9%+12.6%

1.2. Operating Efficiency of Ultimovacs ASA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Ultimovacs is operating .

  • Measures how much profit Ultimovacs makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Ultimovacs to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ultimovacs ASA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--295.1%+295.1%
TTM--225.8%+225.8%
YOY--288.4%+288.4%
5Y--477.4%+477.4%
10Y--625.6%+625.6%
1.2.2. Operating Ratio

Measures how efficient Ultimovacs is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Ultimovacs ASA:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.090-3.090
TTM-3.264-3.264
YOY-3.783-3.783
5Y-5.679-5.679
10Y-7.894-7.894

1.3. Liquidity of Ultimovacs ASA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Ultimovacs is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.85 means the company has kr4.85 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Ultimovacs ASA:

  • The MRQ is 4.850. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.000. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.850TTM7.000-2.150
TTM7.000YOY16.938-9.938
TTM7.0005Y17.706-10.706
5Y17.70610Y16.514+1.192
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8503.914+0.936
TTM7.0004.220+2.780
YOY16.9385.388+11.550
5Y17.7066.045+11.661
10Y16.5146.406+10.108
1.3.2. Quick Ratio

Measures if Ultimovacs is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Ultimovacs to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off kr0.00 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ultimovacs ASA:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM5.793-5.793
TTM5.793YOY17.060-11.267
TTM5.7935Y12.975-7.182
5Y12.97510Y10.873+2.102
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.572-3.572
TTM5.7933.998+1.795
YOY17.0605.390+11.670
5Y12.9755.969+7.006
10Y10.8736.287+4.586

1.4. Solvency of Ultimovacs ASA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Ultimovacs assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Ultimovacs to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.20 means that Ultimovacs assets are financed with 20.0% credit (debt) and the remaining percentage (100% - 20.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Ultimovacs ASA:

  • The MRQ is 0.200. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.155. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.200TTM0.155+0.044
TTM0.155YOY0.079+0.076
TTM0.1555Y0.092+0.063
5Y0.09210Y0.095-0.003
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2000.336-0.136
TTM0.1550.334-0.179
YOY0.0790.269-0.190
5Y0.0920.366-0.274
10Y0.0950.390-0.295
1.4.2. Debt to Equity Ratio

Measures if Ultimovacs is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Ultimovacs to the Biotechnology industry mean.
  • A Debt to Equity ratio of 24.9% means that company has kr0.25 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ultimovacs ASA:

  • The MRQ is 0.249. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.185. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.249TTM0.185+0.064
TTM0.185YOY0.087+0.098
TTM0.1855Y0.103+0.082
5Y0.10310Y0.107-0.003
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2490.382-0.133
TTM0.1850.396-0.211
YOY0.0870.335-0.248
5Y0.1030.434-0.331
10Y0.1070.465-0.358

2. Market Valuation of Ultimovacs ASA

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Ultimovacs generates.

  • Above 15 is considered overpriced but always compare Ultimovacs to the Biotechnology industry mean.
  • A PE ratio of -18.89 means the investor is paying kr-18.89 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ultimovacs ASA:

  • The EOD is -1.278. Based on the earnings, the company is expensive. -2
  • The MRQ is -18.885. Based on the earnings, the company is expensive. -2
  • The TTM is -18.119. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.278MRQ-18.885+17.607
MRQ-18.885TTM-18.119-0.767
TTM-18.119YOY-18.232+0.114
TTM-18.1195Y-14.493-3.626
5Y-14.49310Y-12.078-2.416
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.278-2.259+0.981
MRQ-18.885-2.569-16.316
TTM-18.119-2.664-15.455
YOY-18.232-4.120-14.112
5Y-14.493-6.258-8.235
10Y-12.078-6.171-5.907
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Ultimovacs ASA:

  • The EOD is -1.685. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -24.906. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -20.623. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.685MRQ-24.906+23.221
MRQ-24.906TTM-20.623-4.283
TTM-20.623YOY-17.146-3.478
TTM-20.6235Y-17.199-3.425
5Y-17.19910Y-14.332-2.866
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.685-2.924+1.239
MRQ-24.906-3.246-21.660
TTM-20.623-3.488-17.135
YOY-17.146-5.620-11.526
5Y-17.199-8.315-8.884
10Y-14.332-8.826-5.506
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Ultimovacs is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 15.12 means the investor is paying kr15.12 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Ultimovacs ASA:

  • The EOD is 1.023. Based on the equity, the company is underpriced. +1
  • The MRQ is 15.122. Based on the equity, the company is expensive. -2
  • The TTM is 10.490. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1.023MRQ15.122-14.099
MRQ15.122TTM10.490+4.632
TTM10.490YOY5.473+5.017
TTM10.4905Y5.451+5.039
5Y5.45110Y4.543+0.909
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.0231.851-0.828
MRQ15.1222.090+13.032
TTM10.4902.095+8.395
YOY5.4732.844+2.629
5Y5.4513.466+1.985
10Y4.5433.815+0.728
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Ultimovacs ASA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.423-1.235-13%-1.045-27%0.174-920%0.338-521%
Book Value Per Share--8.12010.275-21%15.003-46%13.326-39%11.863-32%
Current Ratio--4.8507.000-31%16.938-71%17.706-73%16.514-71%
Debt To Asset Ratio--0.2000.155+28%0.079+151%0.092+117%0.095+111%
Debt To Equity Ratio--0.2490.185+35%0.087+187%0.103+141%0.107+134%
Dividend Per Share----0%-0%-0%-0%
Eps---1.626-1.442-11%-1.219-25%-1.047-36%-0.940-42%
Free Cash Flow Per Share---1.233-1.386+12%-1.167-5%-1.073-13%-1.073-13%
Free Cash Flow To Equity Per Share---1.233-1.406+14%-1.141-7%-0.325-74%-0.325-74%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---87.600--------
Intrinsic Value_10Y_min---74.391--------
Intrinsic Value_1Y_max---5.233--------
Intrinsic Value_1Y_min---5.138--------
Intrinsic Value_3Y_max---18.425--------
Intrinsic Value_3Y_min---17.536--------
Intrinsic Value_5Y_max---34.875--------
Intrinsic Value_5Y_min---32.137--------
Market Cap285914691.000-1378%4225069080.0003574793790.000+18%2764530135.000+53%2309337432.000+83%1924447860.000+120%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio1.023-1378%15.12210.490+44%5.473+176%5.451+177%4.543+233%
Pe Ratio-1.278+93%-18.885-18.119-4%-18.232-3%-14.493-23%-12.078-36%
Price Per Share8.310-1378%122.800103.900+18%80.350+53%67.120+83%55.933+120%
Price To Free Cash Flow Ratio-1.685+93%-24.906-20.623-17%-17.146-31%-17.199-31%-14.332-42%
Price To Total Gains Ratio-5.839+93%-86.282-91.618+6%-105.513+22%-78.743-9%-78.743-9%
Quick Ratio---5.793-100%17.060-100%12.975-100%10.873-100%
Return On Assets---0.160-0.118-26%-0.077-52%-0.073-55%-0.074-54%
Return On Equity---0.200-0.141-30%-0.085-58%-0.082-59%-0.083-59%
Total Gains Per Share---1.423-1.235-13%-1.045-27%0.174-920%0.338-521%
Usd Book Value--25312915.20032028685.500-21%46766746.050-46%41539071.690-39%36979163.875-32%
Usd Book Value Change Per Share---0.129-0.112-13%-0.095-27%0.016-920%0.031-521%
Usd Book Value Per Share--0.7360.931-21%1.359-46%1.207-39%1.075-32%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.147-0.131-11%-0.110-25%-0.095-36%-0.085-42%
Usd Free Cash Flow---3842346.000-4320872.550+12%-3639175.500-5%-2676573.150-30%-2230477.625-42%
Usd Free Cash Flow Per Share---0.112-0.126+12%-0.106-5%-0.097-13%-0.097-13%
Usd Free Cash Flow To Equity Per Share---0.112-0.127+14%-0.103-7%-0.029-74%-0.029-74%
Usd Market Cap25903871.005-1378%382791258.648323876317.374+18%250466430.231+53%209225971.339+83%174354976.116+120%
Usd Price Per Share0.753-1378%11.1269.413+18%7.280+53%6.081+83%5.068+120%
Usd Profit---5067348.600-4286263.350-15%-3800488.800-25%-3162084.960-38%-2843752.800-44%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.129-0.112-13%-0.095-27%0.016-920%0.031-521%
 EOD+3 -5MRQTTM+11 -18YOY+6 -235Y+5 -2410Y+5 -24

3.2. Fundamental Score

Let's check the fundamental score of Ultimovacs ASA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.278
Price to Book Ratio (EOD)Between0-11.023
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than14.850
Debt to Asset Ratio (MRQ)Less than10.200
Debt to Equity Ratio (MRQ)Less than10.249
Return on Equity (MRQ)Greater than0.15-0.200
Return on Assets (MRQ)Greater than0.05-0.160
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Ultimovacs ASA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5021.138
Ma 20Greater thanMa 509.047
Ma 50Greater thanMa 10062.320
Ma 100Greater thanMa 20094.550
OpenGreater thanClose8.340
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in NOK. All numbers in thousands.

Summary
Total Assets349,039
Total Liabilities69,647
Total Stockholder Equity279,392
 As reported
Total Liabilities 69,647
Total Stockholder Equity+ 279,392
Total Assets = 349,039

Assets

Total Assets349,039
Total Current Assets272,117
Long-term Assets76,923
Total Current Assets
Cash And Cash Equivalents 266,559
Other Current Assets 1
Total Current Assets  (as reported)272,117
Total Current Assets  (calculated)266,560
+/- 5,557
Long-term Assets
Property Plant Equipment 3,674
Goodwill 11,653
Intangible Assets 61,596
Long-term Assets  (as reported)76,923
Long-term Assets  (calculated)76,923
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities56,109
Long-term Liabilities13,538
Total Stockholder Equity279,392
Total Current Liabilities
Accounts payable 11,169
Other Current Liabilities -1
Total Current Liabilities  (as reported)56,109
Total Current Liabilities  (calculated)11,168
+/- 44,941
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt3,713
Long-term Liabilities  (as reported)13,538
Long-term Liabilities  (calculated)3,713
+/- 9,825
Total Stockholder Equity
Total Stockholder Equity (as reported)279,392
Total Stockholder Equity (calculated)0
+/- 279,392
Other
Capital Stock3,441
Common Stock Shares Outstanding 34,406
Net Invested Capital 279,392
Net Working Capital 216,008
Property Plant and Equipment Gross 5,929



Balance Sheet

Currency in NOK. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
166,970
153,292
193,633
189,860
521,364
521,364
489,213
478,041
453,293
573,245
543,328
529,717
494,020
466,495
426,531
655,537
601,559
579,253
549,592
509,672
495,182
437,059
387,742
349,039
349,039387,742437,059495,182509,672549,592579,253601,559655,537426,531466,495494,020529,717543,328573,245453,293478,041489,213521,364521,364189,860193,633153,292166,970
   > Total Current Assets 
162,895
149,376
128,889
121,724
453,234
453,234
420,988
407,611
377,334
493,899
463,323
449,363
417,326
389,954
351,042
582,255
532,115
506,647
477,269
435,579
417,469
360,482
314,256
272,117
272,117314,256360,482417,469435,579477,269506,647532,115582,255351,042389,954417,326449,363463,323493,899377,334407,611420,988453,234453,234121,724128,889149,376162,895
       Cash And Cash Equivalents 
157,760
144,144
123,734
115,540
446,041
446,041
412,025
399,607
367,686
483,159
453,523
440,925
409,288
381,799
347,804
574,168
523,706
486,338
469,063
425,309
405,528
344,104
300,273
266,559
266,559300,273344,104405,528425,309469,063486,338523,706574,168347,804381,799409,288440,925453,523483,159367,686399,607412,025446,041446,041115,540123,734144,144157,760
       Short-term Investments 
0
0
0
0
446,041
446,041
0
0
0
0
453,523
6,941
409,288
570
347,804
5,314
4,750
10,611
2,189
4,990
4,750
4,750
199
0
01994,7504,7504,9902,18910,6114,7505,314347,804570409,2886,941453,5230000446,041446,0410000
       Net Receivables 
4,656
4,943
4,807
5,709
6,501
6,501
8,501
8,004
8,817
8,803
8,378
7,690
6,881
6,714
2,256
6,450
7,345
8,240
5,016
6,271
9,681
14,579
0
0
0014,5799,6816,2715,0168,2407,3456,4502,2566,7146,8817,6908,3788,8038,8178,0048,5016,5016,5015,7094,8074,9434,656
       Other Current Assets 
0
0
0
0
0
0
-1
0
-1
0
1
0
0
570
1
759
0
10,611
2,189
1,083
605
0
199
1
119906051,0832,18910,611075915700010-10-1000000
   > Long-term Assets 
0
0
0
0
0
68,130
68,225
70,430
75,959
79,345
80,005
80,354
76,694
76,541
75,489
73,282
69,444
72,606
72,322
74,093
77,712
76,577
73,487
76,923
76,92373,48776,57777,71274,09372,32272,60669,44473,28275,48976,54176,69480,35480,00579,34575,95970,43068,22568,13000000
       Property Plant Equipment 
763
672
711
736
4,336
4,336
4,001
4,059
4,399
3,893
4,040
4,007
3,465
2,958
2,512
2,163
1,900
2,050
1,994
5,664
5,177
4,674
4,172
3,674
3,6744,1724,6745,1775,6641,9942,0501,9002,1632,5122,9583,4654,0074,0403,8934,3994,0594,0014,3364,336736711672763
       Goodwill 
0
0
10,395
10,981
10,388
10,388
10,473
10,851
11,749
11,578
11,698
11,795
11,295
11,388
11,316
11,031
10,453
10,999
10,993
10,701
11,434
11,358
10,948
11,653
11,65310,94811,35811,43410,70110,99310,99910,45311,03111,31611,38811,29511,79511,69811,57811,74910,85110,47310,38810,38810,98110,39500
       Intangible Assets 
3,311
3,244
53,639
56,418
53,406
53,406
53,751
55,519
59,811
63,873
64,268
64,551
61,934
62,196
61,661
60,088
57,091
59,557
59,335
57,728
61,101
60,544
58,366
61,596
61,59658,36660,54461,10157,72859,33559,55757,09160,08861,66162,19661,93464,55164,26863,87359,81155,51953,75153,40653,40656,41853,6393,2443,311
       Long-term Assets Other 
0
0
0
0
0
0
0
1
0
1
-1
2
0
-1
0
1
0
0
0
-1
0
1
1
0
0110-100010-102-11010000000
> Total Liabilities 
11,409
12,496
23,862
29,956
36,348
36,348
22,006
33,409
33,716
35,248
33,026
41,337
38,694
43,949
44,737
62,384
44,980
33,476
36,541
60,322
72,033
53,890
59,382
69,647
69,64759,38253,89072,03360,32236,54133,47644,98062,38444,73743,94938,69441,33733,02635,24833,71633,40922,00636,34836,34829,95623,86212,49611,409
   > Total Current Liabilities 
11,409
12,496
13,466
18,975
22,288
22,288
8,099
20,257
19,561
17,250
15,246
27,467
25,711
31,278
32,548
50,897
34,135
21,761
24,613
45,907
57,398
39,768
46,137
56,109
56,10946,13739,76857,39845,90724,61321,76134,13550,89732,54831,27825,71127,46715,24617,25019,56120,2578,09922,28822,28818,97513,46612,49611,409
       Accounts payable 
2,591
4,449
1,836
2,978
18,852
18,852
1,895
11,768
10,483
8,671
5,401
8,611
8,323
15,321
4,853
22,555
5,921
6,038
10,527
7,655
21,956
14,021
6,404
11,169
11,1696,40414,02121,9567,65510,5276,0385,92122,5554,85315,3218,3238,6115,4018,67110,48311,7681,89518,85218,8522,9781,8364,4492,591
       Other Current Liabilities 
2,136
1,431
0
1
2,059
2,059
4,777
0
5,934
4,417
5,236
9,896
10,596
7,428
8,058
11,320
17,342
6,662
7,464
0
12,842
12,600
20,731
-1
-120,73112,60012,84207,4646,66217,34211,3208,0587,42810,5969,8965,2364,4175,93404,7772,0592,059101,4312,136
   > Long-term Liabilities 
0
0
0
0
0
14,060
13,907
13,152
14,155
17,997
17,780
13,870
12,983
12,671
12,189
11,487
10,845
11,715
11,927
14,414
14,634
14,121
13,243
13,538
13,53813,24314,12114,63414,41411,92711,71510,84511,48712,18912,67112,98313,87017,78017,99714,15513,15213,90714,06000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
2,075
1,686
1,283
873
457
391
714
935
3,713
3,201
2,763
2,297
0
02,2972,7633,2013,7139357143914578731,2831,6862,07500000000000
       Other Liabilities 
0
0
10,396
10,981
10,389
10,389
10,473
10,850
11,748
16,532
15,681
11,795
11,295
11,387
11,316
11,031
10,453
11,000
10,993
10,702
0
11,359
0
0
0011,359010,70210,99311,00010,45311,03111,31611,38711,29511,79515,68116,53211,74810,85010,47310,38910,38910,98110,39600
> Total Stockholder Equity
155,561
140,796
169,771
159,904
485,016
485,016
467,207
444,632
419,577
537,997
510,302
488,380
455,326
422,546
381,794
593,153
556,579
545,777
513,051
449,350
423,149
383,169
328,360
279,392
279,392328,360383,169423,149449,350513,051545,777556,579593,153381,794422,546455,326488,380510,302537,997419,577444,632467,207485,016485,016159,904169,771140,796155,561
   Common Stock
606
606
641
641
2,786
2,786
2,786
2,786
2,786
3,197
3,197
3,197
3,200
3,200
3,200
3,422
3,422
3,422
3,427
3,440
3,440
3,440
3,440
0
03,4403,4403,4403,4403,4273,4223,4223,4223,2003,2003,2003,1973,1973,1972,7862,7862,7862,7862,786641641606606
   Retained Earnings Total Equity000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
809,214
810,140
810,140
810,140
1,070,841
1,070,841
1,070,841
1,072,212
1,076,308
1,076,308
1,076,308
1,076,308
0
01,076,3081,076,3081,076,3081,076,3081,072,2121,070,8411,070,8411,070,841810,140810,140810,140809,21400000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
1
1
60
2,888
183
183
1,413
4,202
9,484
9,878
12,907
15,568
15,385
19,068
21,623
23,210
23,238
34,812
39,012
41,715
49,625
53,020
54,033
0
054,03353,02049,62541,71539,01234,81223,23823,21021,62319,06815,38515,56812,9079,8789,4844,2021,4131831832,8886011



Balance Sheet

Currency in NOK. All numbers in thousands.




Cash Flow

Currency in NOK. All numbers in thousands.




Income Statement

Currency in NOK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-215,734
Operating Income-215,734-215,734
 
Operating Expense (+$)
Research Development123,834
Selling General Administrative6,476
Selling And Marketing Expenses-
Operating Expense215,734130,310
 
Net Interest Income (+$)
Interest Income14,127
Interest Expense--
Other Finance Cost-382
Net Interest Income13,745
 
Pretax Income (+$)
Operating Income-215,734
Net Interest Income13,745
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-189,239-215,734
EBIT - interestExpense = 0
-189,239
-189,239
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--189,239
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-189,239
Tax Provision-0
Net Income From Continuing Ops-189,239-189,239
Net Income-189,239
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--13,745
 

Technical Analysis of Ultimovacs
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Ultimovacs. The general trend of Ultimovacs is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Ultimovacs's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Ultimovacs ASA.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 13.70 < 58.50 < 59.50.

The bearish price targets are: 6.07.

Tweet this
Ultimovacs ASA Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Ultimovacs ASA. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Ultimovacs ASA Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Ultimovacs ASA. The current macd is -12.3668569.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Ultimovacs price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Ultimovacs. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Ultimovacs price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Ultimovacs ASA Daily Moving Average Convergence/Divergence (MACD) ChartUltimovacs ASA Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Ultimovacs ASA. The current adx is 54.86.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Ultimovacs shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Ultimovacs ASA Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Ultimovacs ASA. The current sar is 6.42943542.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Ultimovacs ASA Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Ultimovacs ASA. The current rsi is 21.14. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Ultimovacs ASA Daily Relative Strength Index (RSI) ChartUltimovacs ASA Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Ultimovacs ASA. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Ultimovacs price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Ultimovacs ASA Daily Stochastic Oscillator ChartUltimovacs ASA Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Ultimovacs ASA. The current cci is -48.62536184.

Ultimovacs ASA Daily Commodity Channel Index (CCI) ChartUltimovacs ASA Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Ultimovacs ASA. The current cmo is -53.40477624.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Ultimovacs ASA Daily Chande Momentum Oscillator (CMO) ChartUltimovacs ASA Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Ultimovacs ASA. The current willr is -92.61168385.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Ultimovacs ASA Daily Williams %R ChartUltimovacs ASA Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Ultimovacs ASA.

Ultimovacs ASA Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Ultimovacs ASA. The current atr is 2.98150773.

Ultimovacs ASA Daily Average True Range (ATR) ChartUltimovacs ASA Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Ultimovacs ASA. The current obv is -41,515,457.

Ultimovacs ASA Daily On-Balance Volume (OBV) ChartUltimovacs ASA Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Ultimovacs ASA. The current mfi is 62.80.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Ultimovacs ASA Daily Money Flow Index (MFI) ChartUltimovacs ASA Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Ultimovacs ASA.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-17WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-27MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Ultimovacs ASA Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Ultimovacs ASA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5021.138
Ma 20Greater thanMa 509.047
Ma 50Greater thanMa 10062.320
Ma 100Greater thanMa 20094.550
OpenGreater thanClose8.340
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Ultimovacs with someone you think should read this too:
  • Are you bullish or bearish on Ultimovacs? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Ultimovacs? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Ultimovacs ASA

I send you an email if I find something interesting about Ultimovacs ASA.


Comments

How you think about this?

Leave a comment

Stay informed about Ultimovacs ASA.

Receive notifications about Ultimovacs ASA in your mailbox!